{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:48:29Z","timestamp":1779889709289,"version":"3.53.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","award":["CD-GT-0918-0746-SEI"],"award-info":[{"award-number":["CD-GT-0918-0746-SEI"]}],"id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ajoc.2023.101849","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T12:44:21Z","timestamp":1681821861000},"page":"101849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Pigmentary retinopathy associated with immune therapy for advanced cutaneous melanoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Andrew C.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamanga","family":"Borooah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajoc.2023.101849_bib1","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"issue":"14","key":"10.1016\/j.ajoc.2023.101849_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajoc.2023.101849_bib3","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2019.01.031","article-title":"Ophthalmic immune-related adverse events of immunotherapy: a single-site case series","volume":"126","author":"Kim","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2023.101849_bib4","series-title":"ASCO Plenary Series","article-title":"DREAMseq: a phase III trial \u2013 ECOG-ACRIN EA6134","author":"Atkins","year":"2021"},{"issue":"11","key":"10.1016\/j.ajoc.2023.101849_bib5","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3928\/23258160-20171030-09","article-title":"Treatment of ipilimumab-induced vogt-koyanagi-harada syndrome with oral dexamethasone","volume":"48","author":"Witmer","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"8","key":"10.1016\/j.ajoc.2023.101849_bib6","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jamaophthalmol.2015.1128","article-title":"Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma","volume":"133","author":"Mantopoulos","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajoc.2023.101849_bib7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3928\/23258160-20150610-10","article-title":"Ipilimumab-associated retinopathy","volume":"46","author":"Crews","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"12","key":"10.1016\/j.ajoc.2023.101849_bib8","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jamaophthalmol.2017.4872","article-title":"Combination ipilimumab and nivolumab for metastatic melanoma associated with ciliochoroidal effusion and exudative retinal detachment","volume":"135","author":"Tsui","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajoc.2023.101849_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/ICB.0000000000000477","article-title":"Bilateral metastatic cutaneous melanoma to retina and vitreous after ipilimumab treated with pars plana vitrectomy and radiotherapy","volume":"12","author":"Kanavati","year":"2018","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"10.1016\/j.ajoc.2023.101849_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12886-020-01495-w","article-title":"Bilateral multiple serous retinal detachments after treatment with nivolumab: a case report","volume":"20","author":"Miyamoto","year":"2020","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajoc.2023.101849_bib11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1159\/000508091","article-title":"Bilateral exudative retinal detachments associated with nivolumab immunotherapy","volume":"11","author":"Ajlan","year":"2020","journal-title":"Case Rep Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajoc.2023.101849_bib12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/08820538.2021.1906916","article-title":"Recurrent episodes with serous retinal detachment and anterior uveitis in a patient using nivolumab (anti -PD-1 antibody) therapy: a case report and literature review","volume":"36","author":"Yilmaz Tugan","year":"2021","journal-title":"Semin Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajoc.2023.101849_bib13","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1097\/WNO.0000000000000909","article-title":"Photopsias in the setting of nivolumab therapy","volume":"41","author":"Ahluwalia","year":"2021","journal-title":"J Neuro Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajoc.2023.101849_bib14","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.survophthal.2021.01.003","article-title":"Pharmacologically induced uveitis","volume":"66","author":"Abdalla Elsayed","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajoc.2023.101849_bib15","article-title":"Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review","volume":"7","author":"Heng","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajoc.2023.101849_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/ICB.0000000000001113","article-title":"VOGT-KOYANAGI-HARADA-LIKE uveitis followed by melanoma-associated retinopathy with focal chorioretinal atrophy and choroidal neovascularization in a patient with metastatic cutaneous melanoma","volume":"17","author":"Ng","year":"2023","journal-title":"Retin Cases Brief Rep"},{"issue":"2","key":"10.1016\/j.ajoc.2023.101849_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00281-008-0114-7","article-title":"Autoimmune retinopathy: a review and summary","volume":"30","author":"Heckenlively","year":"2008","journal-title":"Semin Immunopathol"},{"issue":"9","key":"10.1016\/j.ajoc.2023.101849_bib18","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.4103\/ijo.IJO_786_20","article-title":"An update on autoimmune retinopathy","volume":"68","author":"Dutta Majumder","year":"2020","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajoc.2023.101849_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10633-022-09901-y","article-title":"Melanoma-associated retinopathy with anti-TRPM1 autoantibodies showing concomitant Off-bipolar cell dysfunction","volume":"145","author":"Hung","year":"2022","journal-title":"Doc Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajoc.2023.101849_bib20","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1007\/s11033-022-07540-9","article-title":"\u03b1-Enolase inhibits apoptosis and promotes cell invasion and proliferation of skin cutaneous melanoma","volume":"49","author":"Zhang","year":"2022","journal-title":"Mol Biol Rep"},{"issue":"5","key":"10.1016\/j.ajoc.2023.101849_bib21","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/1878-0261.12872","article-title":"The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells - a case of inter-tumor heterogeneity","volume":"15","author":"Izraely","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ajoc.2023.101849_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40942-017-0104-9","article-title":"Autoimmune retinopathy: a review","volume":"4","author":"Canamary","year":"2018","journal-title":"Int J Retina Vitreous"},{"issue":"2","key":"10.1016\/j.ajoc.2023.101849_bib23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2023.101849_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.preteyeres.2016.02.002","article-title":"Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment","volume":"52","author":"Du","year":"2016","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"10.1016\/j.ajoc.2023.101849_bib25","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ophtha.2009.08.030","article-title":"Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease","volume":"117","author":"Rao","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajoc.2023.101849_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/ICB.0b013e31824f7130","article-title":"Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome","volume":"6","author":"Wong","year":"2012","journal-title":"Retin Cases Brief Rep"},{"issue":"5","key":"10.1016\/j.ajoc.2023.101849_bib27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ophtha.2008.12.004","article-title":"Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma","volume":"116","author":"Yeh","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2023.101849_bib28","article-title":"Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors","volume":"19","author":"Canestraro","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"10.1016\/j.ajoc.2023.101849_bib29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/ICB.0000000000000882","article-title":"Choroidal neovascularization and chorioretinal atrophy in a patient with melanoma-associated retinopathy after ipilimumab\/nivolumab combination therapy","volume":"15","author":"Elwood","year":"2021","journal-title":"Retin Cases Brief Rep"},{"issue":"2","key":"10.1016\/j.ajoc.2023.101849_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CJI.0000000000000066","article-title":"Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma","volume":"38","author":"Crosson","year":"2015","journal-title":"J Immunother"},{"issue":"6","key":"10.1016\/j.ajoc.2023.101849_bib31","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/0360-3016(90)90376-U","article-title":"Effects of ionizing radiation on the blood brain barrier permeability to pharmacologically active substances","volume":"19","author":"Trnovec","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ajoc.2023.101849_bib32","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3389\/fimmu.2019.01975","article-title":"Microglia in retinal degeneration","volume":"10","author":"Rashid","year":"2019","journal-title":"Front Immunol"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993623000579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993623000579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:00:12Z","timestamp":1762527612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993623000579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":32,"alternative-id":["S2451993623000579"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2023.101849","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pigmentary retinopathy associated with immune therapy for advanced cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2023.101849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101849"}}